Phase Ib dose-finding trial of lapatinib plus pegylated liposomal doxorubicin in advanced HER2-positive breast cancer
Open Access
- 24 March 2017
- journal article
- research article
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 79 (5) , 863-871
Abstract
Combination of anthracyclines with trastuzumab is hampered by cardiotoxicity. Pegylated liposomal doxorubicin and lapatinib could represent a safer alternative to combination therapy.Keywords
This publication has 36 references indexed in Scilit:
- Pegylated Liposomal DoxorubicinDrugs, 2011
- Impact of anti-HER2 therapy on overall survival in HER2-overexpressing breast cancer patients with brain metastasesBritish Journal of Cancer, 2011
- Single-agent pegylated liposomal doxorubicin (PLD) in the treatment of metastatic breast cancer: results of an Austrian observational trialBMC Cancer, 2011
- A Synergistic Interaction between Lapatinib and Chemotherapy Agents in a Panel of Cell Lines Is Due to the Inhibition of the Efflux Pump BCRPMolecular Cancer Therapeutics, 2010
- Deconstructing the molecular portraits of breast cancerMolecular Oncology, 2010
- Anthracycline rechallenge using pegylated liposomal doxorubicin in patients with metastatic breast cancer: a pooled analysis using individual data from four prospective trialsBritish Journal of Cancer, 2010
- Underuse of Anthracyclines in Women with HER-2+ Advanced Breast CancerThe Oncologist, 2010
- Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptor–Positive Metastatic Breast CancerJournal of Clinical Oncology, 2009
- Role of efflux pump activity in lapatinib/caelyx combination in breast cancer cell linesAnti-Cancer Drugs, 2009
- Expression of p95HER2, a Truncated Form of the HER2 Receptor, and Response to Anti-HER2 Therapies in Breast CancerJNCI: Journal of the National Cancer Institute, 2007